This multidisciplinary conference will integrate emerging technologies and immunobiology to advance genetic engineering of immune cells to treat cancer and other pathologies. Main themes include strategies to identify novel immune targets, enhance the function of synthetic and natural antigen receptors, and genetically engineer and edit T cells and their precursors.
The conference will also cover mechanisms of resistance to cell-based immunotherapies and antigen escape in the context of the tumor microenvironment, and how to overcome these challenges. We will also explore the engineering of alternative cell types, including NK cells and pluripotent stem cell-derived immune cells, and their potential to overcome current barriers to immunotherapy.
As a joint meeting with the Keystone Symposia on “Precision Genome Engineering,” all attendees will gain access to both meetings and joint sessions to promote cross-disciplinary collaboration and innovation in tools, technologies and applications for cellular therapies.
Hematopoietic and Pluripotent Stem Cell Editing (joint session)
Shannon Weiman earned her PhD in Biomedical Sciences from the University of California, San Diego, specializing in microbiology and immunology. Prior to joining the Keystone Symposia team, she worked as a freelance writer for leaders in academic, industry and government research, including Stanford University’s Biomedical Innovation Initiative, the University of Colorado’s Biofrontiers Program, UCSF, the FDA and the American Society for Microbiology.